Overview
This is a prospective, multi-site, randomised, sham-controlled, single-blind (outcome assessor-blinded) study designed to assess the effects of Pharyngeal Electrical Stimulation (PES) (using Phagenyx®) for the treatment of oropharyngeal dysphagia after invasive mechanical ventilation (of any duration) by means of naso or oro-tracheal tube in critically ill intensive care unit (ICU) patients.
Description
The PhINEST study is designed to assess the effects of Pharyngeal Electrical Stimulation (PES) (using Phagenyx®) for treatment of oropharyngeal dysphagia after invasive mechanical ventilation (of any duration) by means of naso or oro-tracheal tube in critically ill intensive care unit (ICU) patients.
The main clinical outcomes assessing unsafe swallows and dysphagia severity will be measured using the gold standard, i.e. Fiberoptic Endoscopic Evaluation of Swallowing (FEES) and bedside swallowing assessments on day 2* after completion of final PES treatment.
Randomisation will be on a 1:1 basis at each site stratified for neurological vs. non-neurological reason for admission (Acute Physiology and Chronic Health Evaluation (APACHE) IV diagnostic group). Patients will receive either PES/sham treatment in addition to standard supportive ICU care and standard of care treatments for dysphagia. Administration of all protocol-specific assessments will be conducted by personnel blinded to treatment assignment.
The study will follow an adaptive population enrichment and sample size re-estimation (SSR) design with one interim look. The study will start with a planned sample size of 200 patients and a maximum (evaluable) sample size of 360. Interim analysis after completion of approximately 140 (evaluable) patients will determine:
I. futility stopping; OR II. sample size increase for the overall sampled population; OR III. Enrichment based on the composite primary endpoint by pre-defined subgroups (neurological vs. non-neurological reason for admission according to APACHE IV diagnostic groups). Thus enrollment of patients in the non-performing sub-group will be stopped at the interim while a sample-size re-estimation based on conditional power will be carried out for the other sub-group.
All interim decisions will be based on conditional power which for the Finkelstein-Schoenfeld (FS)-statistic will need to be computed via Monte-Carlo simulations.
Up to thirty (30) investigational sites across Europe are planned to participate in this study which is expected to last 48 months from first patient first visit to last patient last visit. Patients will be assessed at the following intervals: screening, baseline, on day 2* after completion of final study treatment, 7 ± 1 days after final study treatment and 14 ± 1 days after final study treatment (or hospital discharge if earlier). 30-day and 90-day mortality data will also be collected from the patients medical notes/electronic heath records/telephone call (no additional visit required).
*The day two (FU1) visit is to be conducted on the second day (~24hrs) following final PES treatment but may, under certain circumstances, be conducted upon/by the fourth day (~60 hrs) following final study treatment in instances where the final study treatment is delivered on late Friday and where FEES assessment is only possible early on Monday as no weekend FEES service is available at the investigation site.
Eligibility
Pre-screening Inclusion Criteria:
All of the following criteria must be met for inclusion:
- Age ≥ 18 ≤ 85,
- Emergency ICU admission (unplanned admission),
- Recent extubation following invasive mechanical ventilation (of any length of time) by means of endotracheal tube,
- Presence of post-extubation dysphagia as determined by the participating Sites' Standard Of Care (SOC).
Screening / Enrolment Criteria:
To be eligible for enrolment in this study, an individual must meet all of the following
additional criteria:
- Presence of written informed consent according to respective national guidelines,
- Dysphagia severity status classified according to PAS on FEES assessment as
'aspiration' (PAS score ≥ 6),
- Richmond Agitation and Sedation Scale (RASS) score within the range of -1 to +2 (i.e.
if score equals -2, -3, -4 or +3, +4, patient is excluded).
Randomisation Inclusion Criteria (post-consent)
The following additional criteria must be met for randomisation:
• Successful placement and subjective tolerance of the Phagenyx® Catheter within 2 days of
extubation.(post consent)
Exclusion Criteria:
An individual who meets any of the following criteria will be excluded from enrolment in
this study:
- Nasal anatomical deformity, nasal airway obstruction; patient who have had recent
oral, nasal or oesophageal surgery or patient presenting with facial and/or cranial
fractures or any other circumstance (e.g. history of oesophageal perforation,
stricture, pouch, resection or rupture) where the placement of a standard nasogastric
feeding tube (NGT) would be deemed unsafe,
- Cardiac or respiratory condition that might render the insertion (placement) of a
catheter into the throat unsafe,
- Permanently implanted electrical devices,
- Are pregnant (pregnancy test) or known lactating women,
- Have non-neurogenic dysphagia (e.g. Cancer-related),
- Any prior tracheostomy,
- Patients who at the time of extubation have any treatment limitation (i.e., palliative
care, life expectancy less than 48 hours, or are moribund), that prevents or would
prevent compliance with study-specific instructions or procedures (as judged by the
investigator),
- Severe cognitive impairment or other reasons that prevents compliance with
study-specific instructions or procedures (as judged by the investigator),
- Previous history of dysphagia of any origin,
- Pre-existing tube feeding of any form (e.g. percutaneous gastric/enteral feeding tube
related to previous injuries indicating previous dysphagia. NGTs are not an exclusion
criterion),
- Participation in another interventional study (medicinal or device) that could
influence the outcomes of PES,
- Treatment of dysphagia with other forms of electrical stimulation.